{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["26(3)"],"submitter":["Barreiro A"],"pubmed_abstract":["Current COVID-19 vaccines have been associated with a decline in infection rates, prevention of severe disease, and a decrease in mortality rates. However, SARS-CoV-2 variants are continuously evolving, and development of new accessible COVID-19 vaccines is essential to mitigate the pandemic. Here, we present data on preclinical studies in mice of a receptor-binding domain (RBD)-based recombinant protein vaccine (PHH-1V) consisting of an RBD fusion heterodimer comprising the B.1.351 and B.1.1.7 SARS-CoV-2 variants formulated in SQBA adjuvant, an oil-in-water emulsion. A prime-boost immunisation with PHH-1V in BALB/c and K18-hACE2 mice induced a CD4<sup>+</sup> and CD8<sup>+</sup> T cell response and RBD-binding antibodies with neutralizing activity against several variants, and also showed"],"journal":["iScience"],"pagination":["106126"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9893798"],"repository":["biostudies-literature"],"pubmed_title":["Preclinical evaluation of a COVID-19 vaccine candidate based on a recombinant RBD fusion heterodimer of SARS-CoV-2."],"pmcid":["PMC9893798"],"pubmed_authors":["Molas M","Trinite B","Sistere-Oro M","Bech-Sabat G","Pradenas E","Vergara-Alert J","Prat Cabanas T","Prado JG","Moreno A","Lorca-Oro C","Roca M","Moros A","Roca N","Diaz Pedroza J","Cebollada Rica P","Puigvert Molas E","Ortiz R","Blanco J","Perez M","Ferrer L","Madrenas L","Barreiro A","Panosa C","Pentinat-Pelegrin T","Perozo Mur E","Gonzalez-Gonzalez L","Segales J","Iglesias-Fernandez J","Pol Vilarrassa E","Fernandez A","Palmada J","Fernandez-Bastit L","Rodon J","March R","Marfil S","Barretina J","Clotet B","Canete M","Meyerhans A","Ampudia Carrasco R","Capdevila Larripa S","Corominas J","Rosales Salgado Y","Prenafeta A","Garriga C","Loubat-Casanovas J"],"additional_accession":[]},"is_claimable":false,"name":"Preclinical evaluation of a COVID-19 vaccine candidate based on a recombinant RBD fusion heterodimer of SARS-CoV-2.","description":"Current COVID-19 vaccines have been associated with a decline in infection rates, prevention of severe disease, and a decrease in mortality rates. However, SARS-CoV-2 variants are continuously evolving, and development of new accessible COVID-19 vaccines is essential to mitigate the pandemic. Here, we present data on preclinical studies in mice of a receptor-binding domain (RBD)-based recombinant protein vaccine (PHH-1V) consisting of an RBD fusion heterodimer comprising the B.1.351 and B.1.1.7 SARS-CoV-2 variants formulated in SQBA adjuvant, an oil-in-water emulsion. A prime-boost immunisation with PHH-1V in BALB/c and K18-hACE2 mice induced a CD4<sup>+</sup> and CD8<sup>+</sup> T cell response and RBD-binding antibodies with neutralizing activity against several variants, and also showed","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Mar","modification":"2026-05-28T20:09:49.741Z","creation":"2025-04-04T21:09:33.861Z"},"accession":"S-EPMC9893798","cross_references":{"pubmed":["36748086"],"doi":["10.1016/j.isci.2023.106126"]}}